Business Outline

Research & Development Network

Okayama University (Japan) Okayama University (Japan)
Professor Toshiyoshi Fujiwara is a professor of School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University. Professor Fujiwara is co-founder and special advisor of Oncolys BioPharma, and is conducting clinical research for OBP-301 (Telomelysin®) at Okayama University.
Osaka University Osaka University
Professor Hiroyuki Mizuguchi is a professor of Graduate School and School of Pharmaceutical Sciences Biochemistry and Molecular Biology, Osaka University. Professor Mizuguchi is a co-inventor of OBP-401 (TelomeScan®) and OBP-1101 (TelomeScan F35)
*Professor Mizuguchi also holds the post of Chief project leader for Laboratory of Stem Cell Regulation in National Institute of Biomedical Innovation (Japan).
Kyoto Prefectural University of Medicine (Japan) Kyoto Prefectural University of Medicine (Japan)
Professor Toshiyuki Sakai is a head of Research Promotion Center and a professor of Division of Preventive Medicine, Kyoto Prefectural University of Medicine. Oncolys BioPharma jointly conducts the research of OBP-801 with Professor Sakai.
Kagoshima University (Japan) Kagoshima University (Japan)
Professor Masanori Baba is a professor of Division of Antiviral Chemotherapy at Center for Chronic Viral Diseases, Kagoshima University. Professor Baba is a co-inventor of OBP-601 (Censavudine) and Oncolys BioPharma jointly conducts the research of AI-002 with Professor Baba.
Astellas Pharma Inc. (Japan) Astellas Pharma Inc. (Japan)
Oncolys BioPharma made an exclusive license agreement for OBP-801.
Yale University (U.S.A.) Yale University (U.S.A.)
Oncolys BioPharma is granted by Yale University a license for OBP-601 (Censavudine).
Biologics Consulting Group, Inc. (U.S.A.) Biologics Consulting Group, Inc. (U.S.A.)
Oncolys BioPharma receives consulting service on implementing clinical trial based on protocol, filing an IND (Investigational New Drug) application in the U.S.A., dealing with FDA (U.S. Food and Drug Administration).
Lonza Houston, Inc. (U.S.A.) Lonza Houston, Inc. (U.S.A.)
We are in a manufacturing services agreement with Lonza Houston, Inc.
Geron Corporation (U.S.A.) Geron Corporation (U.S.A.)
Oncolys BioPharma is granted by Geron Corporation an exclusive worldwide license concerning human telomerase specific reverse transcriptase (hTERT) promoter for diagnostic use in cancer.
Medigen Biotechnology Corp. (Taiwan) Medigen Biotechnology Corp. (Taiwan)
We made a strategic alliance agreement for OBP-301 (Telomelysin®) with Medigen Biotechnology Corp.
WONIK CUBE Corp. (Korea) WONIK CUBE Corp. (Korea)
Oncolys signed an exclusive license agreement for OBP-1101 in Korea with Wonik Cube in 2014.
Liquid Biotech USA, Inc. (U.S.A.) Liquid Biotech USA, Inc. (U.S.A.)
We entered into an exclusive license agreement for OBP-401 in North America with Liquid Biotech USA in 2015.

Further information on Oncolys BioPharma's approach to partnering and areas of interest »

pagetop